The FDA, which issued India’s Laurus Synthesis a Form 483 in January, followed up the action with an "untitled letter" (PDF) that outlined the Indian drugmaker’s problems with its quality control unit ...

Indian equity markets remain in a tight range in the weekly expiry session on Thursday. However, pockets of opportunity are emerging, with SEBI-registered analysts Kavita Agrawal and Vinay Taparia ...

When Dr Satyanarayana Chava started Laurus Labs in 2007, he invested nearly Rs 60 crore of his own money into it. His confidence in its success was neither bravado nor bluster, but defined by his ...

Hyderabad: Laurus Bio, a subsidiary of Hyderabad-based biopharma player Laurus Labs Ltd, has secured an equity investment of Rs 120 crore from Eight Roads Ventures and F-Prime Capital. Laurus Labs ...

Laurus Labs latest update leaves the fair value estimate at roughly ₹821.93 per share with a steady discount rate of 12.76%, underscoring that the market narrative is shifting more on expectations ...

Laurus Labs API segment is also well set to clock strong growth backed by the company’s increasing focus to diversify into new therapy areas - anti-diabetes and cardiology along with an eye to gain a ...

Revenue: INR1,570 crores, reflecting a 31% year-on-year growth. Gross Margin: 59%, an increase of more than 4% due to better product mix and process improvements. EBITDA: INR389 crores with a margin ...

Laurus Labs has announced an investment of up to €5 million (about Rs 45 crore) in its joint venture KRKA Pharma. The investment is expected to be completed by December 31, 2025. KRKA d.d., Novo mesto ...

Laurus Labs rallies to 52-week high after strong Q1, but analysts remain cautious with downside risk of up to 33 per cent. Laurus Labs has gained 18.36 per cent in the past month. Shares of Laurus ...